“ Celemics’ TrueRepertoire™ Solution overcomes the limitations of
current antibody discovery methodologies and NGS-based immune
repertoire analysis through ”
Because the in vitro screening method currently used in antibody discovery selects clones at random then
proceeds with an assay, there is a high chance of repeated discovery for antibodies existing in large quantities
and a low chance of discovery for antibodies of low frequencies with various characteristics and binding capacities.
In contrast, if the in vitro screening and DNA sequence analysis steps are switched to confirm the antibody
sequences inside the library and their binding capacities are checked without repeating identical antibodies,
clients are able to increase the number of clones with confirmed binding capacities and decrease the cost in
relation to the number of confirmed clones when compared to ELISA analysis.
Therefore, clients can discover rare clones previously undetected with existing technology and are also able to
drastically decrease the associated time and cost.